Gottlieb slams ‘Kabuki’ biosimilar pricing schemes

FDA Commissioner Scott Gottlieb Wednesday criticized PBMs and payers for creating “Kabuki” drug pricing schemes “that obscure profit taking across the supply chain that drives up costs; that expose consumers to high out-of-pocket spending; and that actively discourage competition.” We are “living in a world where financial toxicity is a real concern

Read the full 522 word article

User Sign In